Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312671 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
A Phase 2 study of Bladder Cancer and Urothelial Carcinoma Bladder, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 2
- Study locations
NCT05312671 is a Phase 2 study of Bladder Cancer and Urothelial Carcinoma Bladder that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 63 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05312671, a Phase 2 study of Bladder Cancer and Urothelial Carcinoma Bladder, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination therapy of atezolizumab, platinum, and etoposide.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Etoposide
- PROCEDURE Cystectomy
Study Locations (2)
District of Columbia
- Johns Hopkins University: Sibley Memorial Hospital - Washington D.C.
Maryland
- Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2022-06-27 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312671
The ClinicalTrials.gov registry entry for NCT05312671 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05312671 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT05312671 about?
NCT05312671 is a clinical study titled "Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer". This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination ...
What is the current status of trial NCT05312671?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2022-06-27. Estimated completion is 2029-10.
What conditions does trial NCT05312671 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma Bladder, Small Cell Neuroendocrine Carcinoma of Bladder.
What interventions are being tested in trial NCT05312671?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT05312671?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312671 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
-
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Bladder Cancer
All registered trials for this condition
Urothelial Carcinoma Bladder
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.